3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
45
Breast Neoplasms
15
Leiomyoma
3
Cardiovascular Diseases
3
Polycystic Ovary Syndrome
2
Neoplasms
2
Endometrial Neoplasms
2
Advanced Breast Cancer
2
Stage II Prostate Adenocarcinoma
1
Sexual Dysfunctions, Psychological
1
Sarcopenia
1
Salivary Gland Adenoma, Pleomorphic
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatectomy
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Pelvic Pain
1
Oligometastatic Prostate Carcinoma
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer
1
Metabolic Syndrome
1
Metabolic Diseases
1
Kallmann Syndrome
1
Inflammatory Breast Neoplasms
1
Infertility
1
Hypogonadism
1
Hyperprolactinemia
1
Interventions
Paclitaxel
11
Carboplatin
8
Radiotherapy
6
Cyclophosphamide
6
Trastuzumab
5
Chemotherapy, Adjuvant
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
Epirubicin
3
Doxorubicin
3
Cryosurgery
3
Cisplatin
3
pertuzumab
2
Surgical Procedures, Operative
2
Radiotherapy, Conformal
2
Radiation
2
Letrozole
2
Lapatinib
2
Cryotherapy
2
Brachytherapy
2
talimogene laherparepvec
1
sargramostim
1
ferric carboxymaltose
1
atezolizumab
1
aldesleukin
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Zoledronic Acid
1
Vorinostat
1
VPS Coriolus versicolor extract
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Ductal, Breast
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT02221999
2023-08-29
SHPD002
RenJi Hospital
Phase 2/3
Active not recruiting
250 enrolled